Two GLP-1 medications lead the conversation about medical weight loss: semaglutide and tirzepatide. Both are weekly injections, both are well studied and both can produce meaningful weight loss. They are not the same, though, and for many patients the difference matters. Here is how they compare, and why tirzepatide is the medication we use at Lotus MD.
What is GLP-1, and why does it matter for weight loss?
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It tells your brain you are full, slows the emptying of your stomach and helps regulate blood sugar by prompting insulin release. It is one of the body's main tools for appetite and metabolic control.
Many people who struggle with stubborn weight do not get enough of that signal, or do not respond to it well. Hunger stays high, fullness arrives late, cravings persist, and the cycle continues regardless of effort.
GLP-1 receptor agonists are medications that mimic this hormone and restore the fullness and metabolic signals many patients are missing. The effect goes beyond appetite: they change how the body handles food, blood sugar and fat storage.
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist first developed for type 2 diabetes under the brand name Ozempic. It was later approved for chronic weight management in adults as Wegovy, in 2021.
It binds to GLP-1 receptors in the brain and gut, which reduces appetite and food intake and slows stomach emptying. In its main weight loss trial, people lost about 15 percent of their body weight on average over 68 weeks, a result that changed how medicine approaches weight management.
Semaglutide is a once-weekly injection under the skin, with the dose raised gradually over several months to reduce stomach side effects. It remains widely used and well studied, with a strong safety record.
What is tirzepatide, and what makes it different?
Tirzepatide works differently from semaglutide in one important way: it is a dual agonist.
Semaglutide targets only the GLP-1 receptor. Tirzepatide activates both the GLP-1 receptor and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is a second metabolic hormone that works alongside GLP-1 on insulin release, fat storage and energy balance. GIP receptors are found in fat tissue, the brain and the pancreas, so tirzepatide acts on pathways semaglutide does not reach.
Tirzepatide was approved by the FDA as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023. In the SURMOUNT-1 trial, people on the highest dose lost about 21 percent of their body weight on average over 72 weeks.
Semaglutide vs. tirzepatide at a glance
| Semaglutide | Tirzepatide | |
|---|---|---|
| How it works | GLP-1 agonist | GLP-1 and GIP dual agonist |
| Receptor targets | One (GLP-1) | Two (GLP-1 and GIP) |
| Average weight loss in its main trial | About 15% of body weight | About 21% at the highest dose |
| How it is given | Weekly injection | Weekly injection |
| FDA approval for weight | Wegovy (2021) | Zepbound (2023) |
| Common side effects | Nausea and other stomach symptoms | Similar |
Weight loss results
The head-to-head SURMOUNT-5 trial, published in 2025, compared the two directly in adults with obesity. Over 72 weeks, people on tirzepatide lost about 20 percent of their body weight on average, compared with about 14 percent on semaglutide.
How they work
Both medications reduce appetite and slow stomach emptying through the GLP-1 receptor. Tirzepatide's added GIP activity works alongside that, with effects on hunger, fat metabolism and insulin sensitivity. GIP receptors in fat tissue play a direct role in how the body stores and releases fat.
Side effects
Both can cause nausea, vomiting, constipation or diarrhea, especially in the first weeks. These effects are managed by raising the dose gradually and usually ease as your body adjusts. Individual responses vary, which is one reason the dose is set and adjusted by a physician.
Access
Both medications have had supply and insurance coverage problems. Tirzepatide availability has improved, and it is the medication we currently offer at Lotus MD as part of our physician-supervised medical weight loss program.
Why we recommend tirzepatide at Lotus MD
We do not offer both medications and leave patients to guess. After reviewing the clinical evidence and treating patients at our offices, we made tirzepatide our main recommendation for GLP-1 weight loss. Here is why.
- Greater results for the same commitment. Both require a weekly injection and the same lifestyle effort. If the commitment is identical, patients deserve the medication with the stronger results, and the head-to-head data favors tirzepatide.
- Dual metabolic action. Our approach is to treat root causes, not just symptoms. Weight gain is often driven by a mix of hormonal imbalance, insulin resistance and metabolic dysfunction, and tirzepatide's dual mechanism acts on more of those pathways at once.
- Benefits beyond the scale. Tirzepatide improves insulin sensitivity and blood sugar control. For patients with prediabetes, metabolic syndrome or PCOS-related weight gain, conditions we see often, that broader effect matters.
We always do a full consultation and medical review before recommending any medication. Tirzepatide is not right for everyone, and we take that responsibility seriously.
Who is a good candidate for GLP-1 therapy?
GLP-1 medications are not a shortcut. They are a medical treatment for people whose weight is affecting their health and quality of life.
You may be a strong candidate if you:
- have a BMI of 27 or higher, especially with a weight-related condition such as high blood pressure, prediabetes or high cholesterol
- have struggled to keep weight off through diet and exercise alone
- are dealing with metabolic dysfunction, insulin resistance or hormone-related weight gain
- are not pregnant or planning to become pregnant during treatment
- have no personal or family history of medullary thyroid cancer or MEN2 syndrome
- are committed to a physician-supervised program that includes lifestyle guidance, not just medication
GLP-1 therapy may not be appropriate if you:
- have a history of pancreatitis
- have certain thyroid conditions, which we go through in full at your consultation
- take medications with significant interactions
- are not ready for the gradual dose increases and monitoring the program needs
The only way to know is a proper consultation and medical review. At Lotus MD, we assess every patient individually, including health history, current medications, metabolic markers and goals, before recommending a plan.
What to expect from GLP-1 treatment at Lotus MD
Our program is built around physician supervision, not a prescription and a goodbye.
- Initial consultation. A full assessment of your health history, medications and goals, and whether tirzepatide suits you. We also use InBody 380S body composition analysis to set a baseline: your muscle mass, fat distribution and metabolic age, not just your weight.
- A personal treatment plan. If tirzepatide is appropriate, we build a dosing schedule for you, starting low and increasing gradually. Your plan includes nutrition guidance, activity recommendations, and sleep and stress support, because medication alone only goes so far.
- Ongoing monitoring. Regular check-ins to track progress, adjust your dose, manage side effects and keep you accountable. We follow body composition, so you can see how your muscle-to-fat ratio is changing.
- Long-term strategy. Our goal is not to keep you on medication indefinitely. We help you build the habits and lifestyle foundation that hold your results after the active phase.
Frequently asked questions
Is tirzepatide better than semaglutide?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced more weight loss than semaglutide: about 20 percent of body weight on average versus about 14 percent over 72 weeks. Its dual GLP-1 and GIP action also has broader metabolic effects. For most patients who qualify, we consider tirzepatide the stronger option.
How quickly will I lose weight on tirzepatide?
Most patients notice less appetite within the first one to two weeks. Measurable weight loss usually shows by week four to eight, with the largest results building over six to twelve months as the dose increases. Results vary with starting weight, lifestyle and metabolic health.
What are the side effects of tirzepatide?
The most common side effects affect the stomach and bowel: nausea, constipation, mild diarrhea or reduced appetite. They are strongest in the early weeks and usually ease as your body adjusts, and the gradual dose increases are designed to limit them. Serious side effects are rare, and we go through them in full at your consultation.
Do I need to stay on tirzepatide forever?
Not necessarily. Some patients use GLP-1 therapy to reach significant weight loss and then keep their results through lifestyle changes with their provider's support. Others benefit from an ongoing low maintenance dose. We decide this with each patient based on their goals and health.
Can I get tirzepatide near Roseville or Granite Bay?
Yes. Lotus MD offers physician-supervised tirzepatide treatment at our Sacramento office (Thursday to Saturday) and our Granite Bay office (Monday to Wednesday), both open 9:30 am to 4:30 pm. We see patients from across the greater Sacramento area, including Roseville, Rocklin, Folsom and Citrus Heights.
How is the Lotus MD program different from telehealth weight loss services?
Telehealth platforms usually provide a prescription with little follow-up. Our program is physician-led and includes InBody 380S body composition analysis, ongoing monitoring, lifestyle coaching and a long-term strategy. Dr. Sanghera evaluates every patient personally and stays involved throughout.
How do I get started?
Start with a consultation. We will assess whether tirzepatide is right for you, answer your questions and build a plan around your goals. Read more on our medical weight loss page, see what affects the cost, book an appointment or call (916) 249-7903.
This article is for information only and is not medical advice. GLP-1 medications, including tirzepatide, are prescription treatments and need a physician evaluation to decide whether they suit you. Results vary from person to person.
Sources
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. doi.org/10.1056/NEJMoa2206038
- Aronne LJ, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity" (SURMOUNT-5). New England Journal of Medicine, 2025. doi.org/10.1056/NEJMoa2416394